In a recent real-world study, Pfizer Inc.'s antiviral drug Paxlovid showed lower effectiveness in preventing severe cases of Covid-19 compared to its initial clinical trials. The study, published in JAMA Network Open, found that Paxlovid was only 37% effective at preventing hospitalization or death in high-risk patients, whereas earlier trials had shown a reduction of up to 89%.
It is important to note that the study observed the drug's performance in real-world conditions, rather than within controlled clinical trials. Furthermore, the initial trials were conducted on unvaccinated individuals, which could potentially contribute to the differences in outcomes. Additionally, the coronavirus itself has evolved since those earlier studies, which may also affect the drug's effectiveness.
Despite the reduced efficacy against hospitalization and death, the study emphasizes that Paxlovid remains a crucial drug for combating the worst outcomes of Covid-19. In fact, the study showed it still had an 84% effectiveness in preventing death alone.
Interestingly, the study also compared the efficacy of another therapy, Merck & Co.'s Lagevrio, to Paxlovid. It found that Lagevrio had similar effectiveness, with a 41% reduction in hospitalizations and deaths compared to no treatment. Previous studies had shown reductions of only about 30%. Moreover, Merck's drug demonstrated a 77% effectiveness against death in the study.
The study analyzed electronic health records of 68,867 patients from multiple hospitals in Cleveland and Florida. It also highlighted that Paxlovid may interact with other medications, making Merck's Lagevrio a potential alternative for patients who cannot take Pfizer's drug, although it is not recommended for use in pregnant women.
In conclusion, this real-world study sheds light on the reduced efficacy of Paxlovid in preventing severe cases of Covid-19 compared to its initial trials. Despite this, the drug remains highly recommended for high-risk patients, while Merck's Lagevrio can be considered as an alternative option. Further research and monitoring of the evolving virus are essential in understanding the effectiveness of these antiviral treatments.